Filing Details
- Accession Number:
- 0001209191-17-030981
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-09 16:47:04
- Reporting Period:
- 2017-05-09
- Filing Date:
- 2017-05-09
- Accepted Time:
- 2017-05-09 16:47:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1027035 | W John Childs | C/O Biohaven Pharmaceuticals, Inc. 234 Church Street New Haven CT 06510 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2017-05-09 | 1,035,938 | $0.00 | 2,304,438 | No | 4 | C | Indirect | By the John W. Childs 2013 Revocable Trust |
| Common Shares | Acquisiton | 2017-05-09 | 415,000 | $17.00 | 2,719,438 | No | 4 | P | Indirect | By the John W. Childs 2013 Revocable Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By the John W. Childs 2013 Revocable Trust |
| No | 4 | P | Indirect | By the John W. Childs 2013 Revocable Trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Series A Preferred Shares | Disposition | 2017-05-09 | 1,035,938 | $0.00 | 1,035,938 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- Represents shares received upon conversion of Series A Preferred Shares.
- Effective immediately prior to the closing of the Issuer's initial public offering of its common shares, each Series A Preferred Share automatically converted into one common share of the Issuer. The Series A Preferred Shares had no expiration date.
Billionaire Hedge Funds
